View Older Stories

Feb 25, 2026 08:20AM BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $94 at Bernstein

Feb 25, 2026 06:38AM BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $55 at H.C. Wainwright

Feb 24, 2026 06:48AM BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $68 at Stifel

Feb 23, 2026 04:08PM BioMarin Pharma (BMRN) Misses Q4 EPS by 31c; offers guidance

Feb 12, 2026 09:48AM Baird on BioMarin Pharmaceutical Inc. (BMRN): 'Incrementally negative on competitor data'

Feb 12, 2026 07:41AM BioMarin (BMRN), Ascendis (ASND) Trade Lower Following Competitor Data

Jan 20, 2026 01:08AM Canaccord Genuity Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Buy

Jan 12, 2026 04:46PM BioMarin expects $3.2 billion in 2025 revenue, ROCTAVIAN write-down

Jan 12, 2026 04:06PM BioMarin names Arpit Davé as chief digital and information officer

Dec 22, 2025 09:32AM BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $100 at Truist Securities

Dec 22, 2025 09:08AM BioMarin Pharma (BMRN) discontinues development of BMN 349

Dec 22, 2025 07:09AM BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $60 at H.C. Wainwright

Dec 3, 2025 06:40AM Leerink Partners Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Market Perform

Nov 6, 2025 05:09AM Stifel Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Hold, 'Stock Might Even Be Too Cheap, But It's Getting Harder to See the Path'

Nov 3, 2025 07:08AM BioMarin Pharmaceutical Inc. (BMRN) PT Lowered at Bernstein Amid 'Tough NT Setup'

Oct 28, 2025 09:23AM BioMarin Pharmaceutical Inc. (BMRN) PT Lowered at Truist; 'Competitive Pressures Mounting'

Oct 28, 2025 08:43AM BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $66 at RBC Capital

Oct 28, 2025 06:41AM BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $55 at H.C. Wainwright

Oct 28, 2025 06:07AM BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $73 at Stifel

Oct 28, 2025 04:58AM Wolfe on BioMarin Pharmaceutical Inc. (BMRN): 'Divesting Roctavian Is A Rock Solid Move'

Oct 27, 2025 04:08PM BioMarin Pharma (BMRN) Tops Q3 EPS by 20c

Oct 27, 2025 07:41AM Bernstein's US Biotech 3Q25 Preview: 'Expect Beats from ALNY and REGN'

Oct 14, 2025 06:50AM Cantor Fitzgerald Cuts BioMarin (BMRN) PT to $80 Ahead of 3Q Earnings

Sep 8, 2025 06:48AM H.C. Wainwright Starts BioMarin Pharmaceutical Inc. (BMRN) at Neutral

Aug 30, 2025 04:00PM Why public perception matters so much for biotech valuations

Aug 26, 2025 06:35AM Oppenheimer Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)

Aug 19, 2025 07:08AM BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $95 at Bernstein SocGen Group

Aug 5, 2025 09:29AM Stifel Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)

Aug 5, 2025 09:07AM Cantor Fitzgerald Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)

Aug 5, 2025 06:46AM Bernstein Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)

Aug 5, 2025 06:20AM TD Cowen Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)

Aug 5, 2025 06:12AM BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at UBS

Aug 4, 2025 04:36PM After-hours movers: Palantir, Hims & Hers, Vertex Pharma and more

Aug 4, 2025 04:04PM BioMarin Pharma (BMRN) Tops Q2 EPS by 61c ; Offers Guidance

Jul 15, 2025 06:15AM Wolfe Research Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)

Jul 3, 2025 07:29AM Morgan Stanley Assumes BioMarin Pharmaceutical Inc. (BMRN) at Overweight

Jul 1, 2025 08:46AM BioMarin Pharma (BMRN) Announces Completion of Acquisition of Inozyme (INZY)

Jun 25, 2025 10:03AM Jefferies Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)

Jun 24, 2025 09:02AM BioMarin Pharma (BMRN) Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN at International Society on Thrombosis and Haemostasis 2025 Congress

Jun 5, 2025 12:44PM FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel

May 27, 2025 09:44AM Stifel Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)

May 19, 2025 09:54AM BioMarin Pharmaceutical Inc. (BMRN) PT Raised at Bernstein Following Inozyme Deal

May 16, 2025 01:11PM TD Cowen Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN) Following Inozyme Deal

May 16, 2025 12:22PM Evercore ISI on BioMarin (BMRN): 'INZY Acquisition Looks Like a Solid Addition to the Growing and Often Overlooked Enzyme Therapy Biz'

May 16, 2025 10:11AM Stifel Comments on BioMarin Pharma (BMRN): 'Acquisition of INZY A Strong Strategic Fit for BMRN; The Type of Asset That Offers Value Arbitrage'

May 16, 2025 07:31AM BioMarin Pharma (BMRN) Announces Acquisition of Inozyme Pharma (INZY) for $4 Per Share

May 12, 2025 09:06AM BioMarin Pharma (BMRN) Presents New Data for VOXZOGO in Children with Achondroplasia

May 2, 2025 10:24AM Cantor Fitzgerald Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)

May 1, 2025 04:11PM BioMarin Pharma (BMRN) Tops Q1 EPS by 43c

Apr 21, 2025 06:46AM Oppenheimer Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)

View Older Stories